Načítá se...
Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence‐base review
The evidence supporting therapy with imatinib for bleomycin‐induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopen...
Uloženo v:
| Vydáno v: | Clin Case Rep |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4856242/ https://ncbi.nlm.nih.gov/pubmed/27190613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.549 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|